Q-linea Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Q-linea şirketinin toplam hissedar öz sermayesi SEK25.7M ve toplam borcu SEK78.5M olup, bu da borç-öz sermaye oranını 305.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK138.6M ve SEK112.9M dir.

Anahtar bilgiler

305.9%

Borç/özkaynak oranı

SEK 78.50m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 7.45m
Eşitlik	SEK 25.67m
Toplam yükümlülükler	SEK 112.90m
Toplam varlıklar	SEK 138.56m

Son finansal sağlık güncellemeleri

Recent updates

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Dec 31

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

May 07

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

Jan 11

We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely

Feb 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: QLINEA 'nin kısa vadeli varlıkları ( SEK83.4M ) kısa vadeli yükümlülüklerini ( SEK105.8M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: QLINEA şirketinin kısa vadeli varlıkları ( SEK83.4M ) uzun vadeli yükümlülüklerini ( SEK7.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: QLINEA 'nin net borç/öz sermaye oranı ( 276.8% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: QLINEA şirketinin borç/öz sermaye oranı son 5 yılda 0.2% seviyesinden 305.9% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: QLINEA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: QLINEA un, serbest nakit akışı her yıl % 8.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Q-linea Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely

Recent updates

Consensus revenue estimates fall by 87%

New minor risk - Share price stability

Q-linea AB (publ) Announces the Initiation of a DOOR MAT Study at a Large US Academic Medical Center

Q-Linea AB (Publ) Announces US Reference Laboratory Completes ASTar®? Evaluation

Q-linea AB (publ) Presents Interim Evaluation Data on Webinar

Consensus revenue estimates fall by 42%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Q-linea AB (publ) to Report Q1, 2025 Results on May 03, 2025

Q-linea AB (publ) Approves the Election of Jonas Jarvius as Members of the Board of Directors

Consensus revenue estimates increase by 49%

First quarter 2024 earnings released: kr0.48 loss per share (vs kr2.10 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 24%, EPS downgraded

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB Appoints Anders Ljunggren as Managing Director, Effective 1 March 2024

Q-linea AB (publ) Announces CEO Changes

Q-linea AB (publ) to Report First Half, 2024 Results on Jul 11, 2024

Q-linea AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 27%

Price target decreased by 13% to kr10.00

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB (Publ) Announces Jonas Jarvius to Step Down as CEO Before Summer 2024

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 262.885275 million.

New major risk - Share price stability

Consensus revenue estimates decrease by 40%, EPS upgraded

Q-linea AB (publ) Completes its 510(k) Application for US Market Approval

Second quarter 2023 earnings released: kr2.23 loss per share (vs kr2.53 loss in 2Q 2022)

Q-linea AB (publ) Announces First Patient Enrolls in Lifetimes

Consensus revenue estimates increase by 40%, EPS downgraded

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

CFO & Investor Relations Officer recently bought kr143k worth of stock

Full year 2022 earnings released: kr9.20 loss per share (vs kr8.19 loss in FY 2021)

Q-linea AB (publ) Announces CFO Changes, Effective May 1, 2023

Q-linea AB (publ) Prepare to Start Additional Testing for US 510(K) Application

Q-Linea Participates in Comparative Rapid AST Study

VP & Research Director recently bought kr241k worth of stock

Consensus revenue estimates fall by 21%

Q-linea AB (publ) to Report Q1, 2023 Results on May 04, 2023

Third quarter 2022 earnings released: kr2.03 loss per share (vs kr1.68 loss in 3Q 2021)

Consensus revenue estimates fall by 34%

Second quarter 2022 earnings released: kr2.53 loss per share (vs kr2.47 loss in 2Q 2021)

Consensus revenue estimates fall by 82%

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Price target decreased to kr165

Q-linea AB (publ) Announces Marcus Storch Not Available for Re-Election as Member of Board of Directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

CEO & President recently bought kr480k worth of stock

Insufficient new directors

Now 22% undervalued after recent price drop

Price target decreased to kr165

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

Forecast to breakeven in 2023

Third quarter 2021 earnings released: kr1.68 loss per share (vs kr1.80 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: kr2.47 loss per share (vs kr2.37 loss in 2Q 2020)

CEO & President recently sold kr14m worth of stock

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 301.4 million.

Q-linea AB (publ) Initiates US 510(k) Clinical Study for ASTar

Consensus forecasts updated

First quarter 2021 earnings released: kr2.34 loss per share (vs kr2.44 loss in 1Q 2020)

Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019)

Price target increased to kr185